TY - JOUR
T1 - Stent-based controlled release of intravascular angiostatin to limit plaque progression and in-stent restenosis
AU - Ganaha, Fumikiyo
AU - Kao, Edward Y.
AU - Wong, Humberto
AU - Elkins, Christopher J.
AU - Lee, Jane
AU - Modanlou, Shoreh
AU - Rhee, Ceron
AU - Kuo, Michael D.
AU - Yuksel, Eser
AU - Cifra, Pamela N.
AU - Waugh, Jacob M.
AU - Dake, Michael D.
N1 - Funding Information: Supported in part by an unrestricted grant from the Cordis Corporation (M.D.D.).
PY - 2004/6
Y1 - 2004/6
N2 - PURPOSE: To evaluate the importance of angiogenesis in plaque progression after stent placement, this study examines stent-based controlled delivery of the antiangiogenic agent, angiostatin, in a rabbit model. MATERIALS AND METHODS: Controlled release biodegradable microspheres delivering angiostatin or polymeronly microspheres (polylactic-co-glycolic-acid-polyethylene glycol; PLGA/PEG) were loaded in channeled stents, anchored, and deployed in the aorta of adult New Zealand white rabbits (n = 6 animals per group, three each per time point). The stented aortas were harvested at 7 days and 28 days and evaluated for neovascularization, local inflammation, vascular smooth muscle cell proliferation, and in-stent plaque progression. RESULTS: At 7 days, neovascularization was significantly decreased in the angiostatin groups (1.6 ± 1.6 neovessels per mm2 plaque) versus the control group (15.4 ± 2.6 neovessels per mm2 plaque; P = .00081), as were local inflammation where angiostatin-treated groups demonstrated significantly lower macrophage recruitment per cross section (34.9 ± 4.9 cells per cross section) relative to the control group (55.2 ± 3.84 cells per cross section; P = .0037). And a significant decrease in the overall vascular smooth muscle cell proliferation (143.8 ± 26.3 Ki-67 positive cells per mm 2) relative to the control group (263.2 ± 16.6 Ki-67 positive cells per mm2; P = .00074). At both 7 and 28 days, in-stent plaque progression in the angiostatin groups was successfully limited relative to the control group by 54% (0.255 ± 0.019% of cross section; P = .00016) and 19% (1.981 ± 0.080; P = .0033) respectively and resulted in reduction of in-stent restenosis relative to the control group. CONCLUSION: Angiostatin-eluting stents may limit neovascularity after arterial implantation, offer insight into in-stent restenosis, and allow future refinement of bioactive stent designs and clinical strategies, particularly in light of evidence that intimal smooth muscle cells may in part be marrow-derived.
AB - PURPOSE: To evaluate the importance of angiogenesis in plaque progression after stent placement, this study examines stent-based controlled delivery of the antiangiogenic agent, angiostatin, in a rabbit model. MATERIALS AND METHODS: Controlled release biodegradable microspheres delivering angiostatin or polymeronly microspheres (polylactic-co-glycolic-acid-polyethylene glycol; PLGA/PEG) were loaded in channeled stents, anchored, and deployed in the aorta of adult New Zealand white rabbits (n = 6 animals per group, three each per time point). The stented aortas were harvested at 7 days and 28 days and evaluated for neovascularization, local inflammation, vascular smooth muscle cell proliferation, and in-stent plaque progression. RESULTS: At 7 days, neovascularization was significantly decreased in the angiostatin groups (1.6 ± 1.6 neovessels per mm2 plaque) versus the control group (15.4 ± 2.6 neovessels per mm2 plaque; P = .00081), as were local inflammation where angiostatin-treated groups demonstrated significantly lower macrophage recruitment per cross section (34.9 ± 4.9 cells per cross section) relative to the control group (55.2 ± 3.84 cells per cross section; P = .0037). And a significant decrease in the overall vascular smooth muscle cell proliferation (143.8 ± 26.3 Ki-67 positive cells per mm 2) relative to the control group (263.2 ± 16.6 Ki-67 positive cells per mm2; P = .00074). At both 7 and 28 days, in-stent plaque progression in the angiostatin groups was successfully limited relative to the control group by 54% (0.255 ± 0.019% of cross section; P = .00016) and 19% (1.981 ± 0.080; P = .0033) respectively and resulted in reduction of in-stent restenosis relative to the control group. CONCLUSION: Angiostatin-eluting stents may limit neovascularity after arterial implantation, offer insight into in-stent restenosis, and allow future refinement of bioactive stent designs and clinical strategies, particularly in light of evidence that intimal smooth muscle cells may in part be marrow-derived.
UR - http://www.scopus.com/inward/record.url?scp=2942620071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942620071&partnerID=8YFLogxK
U2 - 10.1097/01.RVI.0000127888.70058.93
DO - 10.1097/01.RVI.0000127888.70058.93
M3 - Article
C2 - 15178721
SN - 1051-0443
VL - 15
SP - 601
EP - 608
JO - Journal of Vascular and Interventional Radiology
JF - Journal of Vascular and Interventional Radiology
IS - 6
ER -